• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-1MEF filed by Catheter Precision Inc.

    8/30/24 6:42:38 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email
    S-1MEF 1 rmed_s1mef.htm FORM S-1MEF rmed_s1mef.htm

     As filed with the Securities and Exchange Commission on August 30, 2024

     

    Registration No. 333- 

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Catheter Precision, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

     3841

     

    38-3661826

    (State or other jurisdiction of

    incorporation or organization)

     

     (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification Number)

     

    1670 Highway 160 West, Suite 205

    Fort Mill, SC 29708

    973-691-2000

     (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

     

    David Jenkins

    Executive Chairman of the Board

    and Chief Executive Officer

    Catheter Precision, Inc.

    1670 Highway 160 West, Suite 205

    Fort Mill, SC 29708

    973-691-2000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to: 

     

    B. Joseph Alley, Jr., Esq.

    Arnall Golden Gregory LLP

    Suite 2100

    171 17th Street NW

    Atlanta, Georgia 30363-1031

    (404) 873-8500

     

    Ivan K. Blumenthal, Esq.

    Daniel Bagliebter, Esq.

    Mintz, Levin, Cohn, Ferris, Glovsky and

    Popeo, P.C.

    919 Third Avenue

    New York, New York 10022

    (212) 935-3000

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-279930 

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

     

    The Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) under the Securities Act of 1933, as amended. 

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-1 is being filed by Catheter Precision, Inc., a Delaware corporation (the “Registrant”), pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction V to Form S-1. This Registration Statement relates to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-279930), initially filed by the Registrant on June 4, 2024 and declared effective, as amended, by the Securities and Exchange Commission on August 29, 2024 (the “Prior Registration Statement”).

     

    This Registration Statement covers the registration of (i) up to $138,000 of common stock units (the “Common Stock Units”), with each Common Stock Unit consisting of one share of Registrant common stock, par value $0.0001, one warrant (a “Series H Warrant”) to purchase one share of common stock (the “Series H Warrant Shares”) that expires on the sixmonth anniversary of the date of issuance, one warrant (a “Series I Warrant”) to purchase one share of common stock (the “Series I Warrant Shares”) that expires on the eighteen month anniversary of the date of issuance, and one warrant (a “Series J Warrant”) to purchase one share of common stock (the “Series J Warrant Shares”) that expires on the five year anniversary of the date of issuance (a “Series J Warrant”), (ii) up to $138,000 of pre-funded units (the “PFW Units”), with each PFW Unit consisting of one pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001 per share with no expiration date, one Series H Warrant, one Series I Warrant, and one Series J Warrant, and (iii) $12,834 of underwriters’ warrants to purchase shares of Common Stock of the Company. PFW Units sold will reduce Common Stock Units sold on a one for one basis. The required opinions of counsel and related consents and accountants’ consents are attached hereto and filed herewith. Pursuant to Rule 462(b), the contents of the Prior Registration Statement, including the exhibits thereto, are incorporated by reference into this Registration Statement.

     

    The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Filing Fee Table exhibit contained in the Prior Registration Statement.

     

     
    2

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    (a) Exhibits. All exhibits filed with or incorporated by reference in the Registration Statement on Form S-1 (SEC File No. 333-279930) are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed herewith, as part of this Registration Statement:

     

    EXHIBIT INDEX

    Exhibit No.

     

    Description

    5.1

     

    Opinion of Arnall Golden Gregory LLP

    23.1

     

    Consent of Withum Smith+Brown, PC, Independent Registered Public Accounting Firm

    23.2

     

    Consent of Haskell & White LLP, Independent Registered Public Accounting Firm

    23.3

     

    Consent of Arnall Golden Gregory LLP (included on Exhibit 5.1)

    24.1**

     

    Power of Attorney (included on the signature page to the Registration Statement on Form S-1 (File No. 333-279930) initially filed with the Commission on June 4, 2024 and incorporated by reference herein)

    107

     

    Filing Fee Table.

     

    ** previously filed

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Park City, State of Utah, on August 30, 2024.

     

     

    CATHETER PRECISION, INC.

     

     

     

     

     

     

    By:

    /s/ David A. Jenkins

     

     

    David A. Jenkins

     

     

    Executive Chairman of the Board and

    Chief Executive Officer

     

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ David A. Jenkins

     

     

     

    August 30, 2024

    David A. Jenkins

     

    Director, Executive Chairman of the Board and Chief Executive Officer

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Margrit Thomassen  

     

     

     

    August 30, 2024

    Margrit Thomassen

     

    Interim Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)

     

     

     

     

     

     

     

    *

     

     

     

    August 30, 2024

    James J. Caruso

     

    Director

     

     

     

     

     

     

     

    *

     

     

     

    August 30, 2024

    Martin Colombatto

     

    Director

     

     

     

    *By:

    /s/ David A. Jenkins

     

    David A. Jenkins

     

    Attorney-in-fact

     

     

    /s/ Andrew Arno

     

     

     

     

    Andrew Arno

     

    Director

     

    August 30, 2024

     

     
    4

     

    Get the next $VTAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catheter Precision Announces Accelerated Momentum for LockeT Device with New Hospital Approvals and Strong Q1 Adoption Outlook

    FORT MILL, S.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a medical device company specializing in advanced electrophysiology solutions, today announced a surge in hospital evaluations and approvals for its LockeT suture retention device. As the company enters the first quarter of 2026, it reports significant progress in domestic and international product adoption, driven by successful clinical outcomes and the device's ability to streamline hospital workflows. Following its highest recorded revenue for the month of January, and following its recent entry into several international markets, Catheter Precision has secured approval for evaluations at several a

    2/4/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Secures Tender From Leading Hospital in Hungary

    FORT MILL, S.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a leading U.S.-based medical device company focusing on advanced solutions in the cardiac electrophysiology market, is proud to announce that its VIVO™ system has successfully secured a significant tender at Albert Szent-Györgyi Health Centre (Szeged University Hospital) in Hungary. This achievement marks Catheter Precision's inaugural installation in Hungary and reinforces its commitment to growth across Central and Eastern Europe. The tender was awarded in partnership with Fototronic, a well-established local distributor. Installation of the VIVO system is anticipated in the first quarter of 2026.

    12/3/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations

    FORT MILL, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on the cardiac electrophysiology marketplace, today reported its results of operations for the quarter and nine months ended September 30, 2025. Highlights of the quarter and nine months include: Financial Highlights Total revenue reported for Q3 2025 was $226,000, an increase of 135% compared with $96,000 in Q3 2024.Total revenue was $581,000 for the nine months ended September 30, 2025, compared with $271,000 for the nine months ended September 30, 2024, an increase of 114%.GAAP net loss for Q3 2025 was $2,251,000, a 45% reduction compared to $

    11/13/25 4:15:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    2/6/26 5:25:30 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    11/21/25 4:15:57 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    11/14/25 5:20:52 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    1/20/26 4:20:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Director Caruso James Joseph converted options into 41 shares, increasing direct ownership by 456% to 50 units (SEC Form 4)

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    12/8/25 4:54:19 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Chairman of the Board and CEO Jenkins David A converted options into 43,006 shares, increasing direct ownership by 695% to 13,799 units (SEC Form 4)

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    12/8/25 4:45:07 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Financials

    Live finance-specific insights

    View All

    Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

    FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th

    5/14/25 4:30:00 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results

    FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.The number of hospitals, inclu

    3/28/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. Announces Third Quarter Update and Financial Results

    FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i

    11/13/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care